Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aldeyra Therapeu
(NQ:
ALDX
)
9.340
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 30, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
9.340
Bid (Size)
7.430 (1)
Ask (Size)
10.29 (1)
Prev. Close
9.340
Today's Range
9.340 - 9.340
52wk Range
2.860 - 10.88
Shares Outstanding
58,576,350
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Recap: Aldeyra Therapeutics Q1 Earnings
May 04, 2023
Via
Benzinga
Aldeyra Therapeutics Reports First-Quarter 2023 Financial Results and Recent Corporate Highlights
May 04, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Performance
YTD
+34.20%
+34.20%
1 Month
-7.34%
-7.34%
3 Month
+38.17%
+38.17%
6 Month
+71.06%
+71.06%
1 Year
+202.27%
+202.27%
More News
Read More
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
May 02, 2023
Via
FinancialNewsMedia
Exposures
COVID-19
Earnings Outlook For Aldeyra Therapeutics
March 08, 2023
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
May 01, 2023
Via
Benzinga
The Week In Charts: 0DTE Options - Too Good To Be True?
April 30, 2023
Via
Talk Markets
Short Volatility Alert: Aldeyra Therapeutics
April 28, 2023
Via
Benzinga
OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay
April 18, 2023
Via
Benzinga
Aldeyra Therapeutics Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis
April 13, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Chart Of The Day: Aldeyra - Skyrocketing
April 11, 2023
Via
Talk Markets
Aldeyra Therapeutics Inc. (NASDAQ: ALDX) Records 52-Week High Monday Morning
April 10, 2023
Via
Investor Brand Network
Aldeyra Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of ADX-629 in Atopic Dermatitis
April 06, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX-629 in Chronic Cough
March 30, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
March 28, 2023
Via
Benzinga
BioNTech, Coinbase Global, Pharming Group And Other Big Stocks Moving Lower On Monday
March 27, 2023
Via
Benzinga
UBS, Credit Suisse And Other Big Stocks Moving Lower In Friday's Pre-Market Session
March 24, 2023
Via
Benzinga
KB Home, Accenture, Netflix And Other Big Stocks Moving Higher On Thursday
March 23, 2023
Via
Benzinga
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX‑2191 in Retinitis Pigmentosa
March 16, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
March 09, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma
March 02, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2022 Financial Results and Discuss Recent Corporate Highlights
March 01, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Highlights 12-Month Safety Data Of Reproxalap In Dry Eye Disease Patients
February 28, 2023
Via
Benzinga
Aldeyra Therapeutics Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Disease
February 28, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Bio-Pharma Company OKYO Pharma Tackles A Common Eye Disease For Which The Current Treatments Aren't Effective Enough
February 23, 2023
Via
Benzinga
Aldeyra Therapeutics Announces Next-Generation RASP-Modulator Drug Candidates Expected to Begin Clinical Trials for Systemic Immune-Mediated Diseases and Geographic Atrophy
February 23, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.